Mylan's Acquisition Strategy Now Focuses On "Bolt-Ons"
This article was originally published in The Pink Sheet Daily
Executive Summary
After three transformative acquisitions, the company aims for 15% CAGR between 2011 and 2013.
You may also be interested in...
Mylan Breathes Life Into Its Specialty Pharma Unit
In its first investor meeting in four years, Mylan lays out plans to barge over the generics industry’s post-2013 so-called ‘reverse patent cliff’ by focusing on high-barrier-to-entry products – including generic Advair – and portfolio and geographic diversification.
India, Japan Shake Hands For Faster Entry Of Generics But Market Realities May Be Tougher To Handle
MUMBAI/TOKYO - Introduction of non-discriminatory or national treatment clauses for Indian generic companies in the latest trade agreement between India and Japan will facilitate wider access for Indian generic firms to the world's second-largest pharma market, but analysts predict headwinds await before companies get a real bang for their buck
Bioniche Purchase Will Move Mylan Into Generic Injectables Market
Bioniche Pharma will be combined with UDL Laboratories to create new Mylan Institutional unit.